Display options
Cite
Venepalli NK, Goff L. Targeting the HGF-cMET Axis in Hepatocellular Carcinoma. Int J Hepatol. 2013;2013:341636doi: 10.1155/2013/341636.
Venepalli, N. K., & Goff, L. (2013). Targeting the HGF-cMET Axis in Hepatocellular Carcinoma. International journal of hepatology, 2013341636. https://doi.org/10.1155/2013/341636
Venepalli, Neeta K, and Goff, Laura. "Targeting the HGF-cMET Axis in Hepatocellular Carcinoma." International journal of hepatology vol. 2013 (2013): 341636. doi: https://doi.org/10.1155/2013/341636
Venepalli NK, Goff L. Targeting the HGF-cMET Axis in Hepatocellular Carcinoma. Int J Hepatol. 2013;2013:341636. doi: 10.1155/2013/341636. Epub 2013 Mar 31. PMID: 23606971; PMCID: PMC3626399.
Copy Download .nbib Format: NLM
Share it on

Int J Hepatol. 2013;2013:341636. doi: 10.1155/2013/341636. Epub 2013 Mar 31.

Targeting the HGF-cMET Axis in Hepatocellular Carcinoma.

International journal of hepatology

Neeta K Venepalli, Laura Goff

Affiliations

  1. Division of Hematology-Oncology, University of Illinois at Chicago, 840 South Wood Street, Suite 820-E, MC 713, Chicago, IL 60612, USA.

PMID: 23606971 PMCID: PMC3626399 DOI: 10.1155/2013/341636

Abstract

Under normal physiological conditions, the hepatocyte growth factor (HGF) and its receptor, the MET transmembrane tyrosine kinase (cMET), are involved in embryogenesis, morphogenesis, and wound healing. The HGF-cMET axis promotes cell survival, proliferation, migration, and invasion via modulation of epithelial-mesenchymal interactions. Hepatocellular cancer (HCC) is the third most common cause of worldwide cancer-related mortality; advanced disease is associated with a paucity of therapeutic options and a five-year survival rate of only 10%. Dysregulation of the HGF-cMET pathway is implicated in HCC carcinogenesis and progression through activation of multiple signaling pathways; therefore, cMET inhibition is a promising therapeutic strategy for HCC treatment. The authors review HGF-cMET structure and function in normal tissue and in HCC, cMET inhibition in HCC, and future strategies for biomarker identification.

References

  1. Transl Oncol. 2012 Oct;5(5):379-92 - PubMed
  2. J Cell Biochem. 2003 Feb 1;88(2):408-17 - PubMed
  3. Nature. 1987 May 21-27;327(6119):239-42 - PubMed
  4. Hepatology. 2009 Feb;49(2):491-503 - PubMed
  5. Biochem Biophys Res Commun. 1998 Mar 27;244(3):683-90 - PubMed
  6. Bioconjug Chem. 2009 Jul;20(7):1299-306 - PubMed
  7. J Clin Oncol. 2011 Dec 20;29(36):4837-8 - PubMed
  8. Hepatogastroenterology. 2008 Mar-Apr;55(82-83):544-9 - PubMed
  9. Hepatology. 1994 Nov;20(5):1231-6 - PubMed
  10. Cancer Res. 2007 Jul 1;67(13):6012-6 - PubMed
  11. Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4477-82 - PubMed
  12. Oncogene. 2010 Sep 9;29(36):4989-5005 - PubMed
  13. Am J Pathol. 2001 Mar;158(3):1111-20 - PubMed
  14. Cancer Res. 1999 Jan 15;59(2):307-10 - PubMed
  15. Clin Cancer Res. 1997 Jul;3(7):1059-66 - PubMed
  16. Mol Cancer Ther. 2011 Dec;10(12):2298-308 - PubMed
  17. Cancer Cell. 2004 Jul;6(1):75-84 - PubMed
  18. Trends Mol Med. 2005 Jun;11(6):284-92 - PubMed
  19. Biochem J. 1997 Sep 15;326 ( Pt 3):763-72 - PubMed
  20. Cancer Sci. 2009 Jul;100(7):1351-8 - PubMed
  21. Int J Cancer. 2005 Feb 10;113(4):678-82 - PubMed
  22. J Biol Chem. 2001 Apr 27;276(17):14308-14 - PubMed
  23. Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2316-21 - PubMed
  24. J Med Chem. 2010 Jan 14;53(1):139-46 - PubMed
  25. Oncogene. 2007 Feb 26;26(9):1276-85 - PubMed
  26. Oncogene. 2004 Jul 8;23(31):5387-93 - PubMed
  27. Proc Natl Acad Sci U S A. 2007 Sep 11;104(37):14592-7 - PubMed
  28. Cancer Cell. 2012 Jul 10;22(1):21-35 - PubMed
  29. Expert Opin Ther Targets. 2012 Jun;16(6):553-72 - PubMed
  30. J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:188-202 - PubMed
  31. Pharmacol Res. 2012 Jan;65(1):23-30 - PubMed
  32. J Biol Chem. 1993 Oct 25;268(30):22927-32 - PubMed
  33. J Cell Biol. 2007 Apr 9;177(1):151-62 - PubMed
  34. Expert Opin Ther Targets. 2008 Aug;12(8):1021-33 - PubMed
  35. J Med Chem. 2009 Feb 26;52(4):943-51 - PubMed
  36. Drug Metab Dispos. 2008 Jul;36(7):1267-74 - PubMed
  37. Science. 1991 Feb 15;251(4995):802-4 - PubMed
  38. Int J Cancer. 2010 Oct 15;127(8):1948-57 - PubMed
  39. Br J Cancer. 2005 Mar 14;92(5):935-41 - PubMed
  40. Int J Cancer. 2012 Mar 15;130(6):1357-66 - PubMed
  41. J Gastrointest Surg. 2008 Feb;12(2):327-37 - PubMed
  42. Hepatology. 1997 Apr;25(4):862-6 - PubMed
  43. J Clin Oncol. 2012 Sep 10;30(26):3287-96 - PubMed
  44. Cancer. 2005 Jan 15;103(2):307-12 - PubMed
  45. J Clin Oncol. 2011 Jul 1;29(19):2660-6 - PubMed
  46. Hepatology. 1994 Jan;19(1):88-91 - PubMed
  47. J Clin Invest. 2006 Jun;116(6):1582-95 - PubMed
  48. Clin Cancer Res. 2012 Apr 15;18(8):2290-300 - PubMed
  49. J Clin Invest. 2000 Dec;106(12):1511-9 - PubMed
  50. Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10608-13 - PubMed
  51. Oncogene. 1997 Dec 18;15(25):3103-11 - PubMed
  52. Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12718-23 - PubMed
  53. Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13264-9 - PubMed
  54. Eur Cytokine Netw. 2010 Dec;21(4):251-6 - PubMed
  55. Nature. 1995 Feb 23;373(6516):702-5 - PubMed
  56. Int J Cancer. 2010 Dec 15;127(12):2893-917 - PubMed
  57. Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12039-44 - PubMed
  58. Zhonghua Wai Ke Za Zhi. 2006 May 1;44(9):603-8 - PubMed
  59. Cancer Res. 2008 May 1;68(9):3314-22 - PubMed
  60. World J Gastroenterol. 2002 Jun;8(3):459-63 - PubMed
  61. Hepatology. 1996 Sep;24(3):575-9 - PubMed
  62. J Biol Chem. 2008 Feb 1;283(5):2675-83 - PubMed
  63. Front Biosci (Schol Ed). 2012 Jun 01;4:1487-515 - PubMed
  64. Semin Cancer Biol. 2001 Apr;11(2):153-65 - PubMed
  65. J Clin Invest. 2004 Nov;114(10):1418-32 - PubMed
  66. Cancer Cell. 2004 Jul;6(1):61-73 - PubMed
  67. Int J Cancer. 2000 Sep 1;87(5):644-9 - PubMed
  68. J Proteome Res. 2010 Feb 5;9(2):798-805 - PubMed
  69. Front Biosci. 2008 Jan 01;13:1943-51 - PubMed
  70. J Gastroenterol. 2004 Dec;39(12):1182-8 - PubMed
  71. Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):692-7 - PubMed
  72. Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25 - PubMed
  73. Cancer Res. 2002 May 15;62(10):2951-6 - PubMed
  74. Science. 1991 Nov 29;254(5036):1382-5 - PubMed
  75. J Biol Chem. 1998 Sep 4;273(36):22913-20 - PubMed
  76. Cell. 1991 Nov 29;67(5):901-8 - PubMed
  77. Liver. 1999 Apr;19(2):151-9 - PubMed
  78. J Immunol. 2012 Aug 15;189(4):1699-707 - PubMed
  79. Biochem Biophys Res Commun. 1999 Aug 19;262(1):76-9 - PubMed
  80. Mol Carcinog. 2003 Mar;36(3):130-41 - PubMed
  81. J Clin Oncol. 2011 Aug 20;29(24):3307-15 - PubMed
  82. J Biol Chem. 2011 Sep 16;286(37):32762-74 - PubMed
  83. Cancer. 2002 Aug 15;95(4):824-34 - PubMed
  84. Cancer Discov. 2012 Mar;2(3):270-87 - PubMed
  85. Mol Cell Biol. 2000 Mar;20(6):2055-65 - PubMed
  86. J Hepatol. 1993 Jun;18(2):168-72 - PubMed

Publication Types